RE:RE:Food for Thought. THTX chart v Immo by Trial PhaseVery much a dream at this point until we see solid efficacy. The timeline on IMMU was probably extended by 2 years because of the safety issues and CRL. But then it did only go about halfway through the Phase 3 before approval since the numbers backed up the Phase 2 data. What you can say is that if your 1b has good data and you move to P2, things can go rather quickly if you don't have safety issues. It seems that much easier with out significant or just even normal SAEs to worry about.
I read another article recently in a cancer jornal about mTNBC and it basically was saying how even the latest drugs (that being IMMU's Trodelvy) are still just a blip in moving the needle and fiding effective treatments for TNBC. Link is below and it reviews the current state of research to try to find ways around the chemo resistance and other resistences. No mention of Sortilin (although there's one mention of progranulin) and a lot about how to tamp down or turn off the genetic traits that lead to resistence in the first place. Very, very complicated and sounds like there's been a lot of deadends in various trials of the things they mention. I actually sent them the recent article on TH1902. Let you know if they say anything but they clearly don't know a whole lot about what the Univ Gothemburg guys or THTX/UQAM are doing.
Triple Negative Breast Cancer: A Mountain Yet to Be Scaled ... SPCEO1 wrote: The ups and downs are pretty impressive - it is a good reminder that if you have something that seems like it may be special, don't get panicked out of the stock on a 50% retracement. And while the run to $40 was great, the buyout at $90 is what made this situation an all-time great stock to own. It does not happen to many stocks, of course, and it probably will not happen to TH, but it is not inconcievable either. We need that phase 1a data before we can really starting dreaming about this type of scenario. And I doubt TH would make it to phase III and approval before getting taken out. I suspect IMMO only got that far due to the various issues they had in the trial.
Wino115 wrote: Food for thought. If the cut/past picture doesn't appear, here's the link:
5x Phase 1 through Phase 2, 4x Phase 2 to Approval. All in, 20x....Equates to $70 a share. Only $7bil mkt cap.
$21bil takeover value ($90) equates to $210 share price for THTX. Is SORT1+ worth more than Trodelvy?
Further, Trodelvy is for only one indication..3L or greater mTNBC. And it received a CRL because of some issues.
Cut the stock in half.
The preclinical was started in 2007 and Fast track was granted late 2014. They started Phase 1 in 2013.
Various safety issues arose as they perfected the drug. So it was not without some hair on it.